All In Biotech

Drug Trial Radar · NCT03689010

To Evaluate the Therapeutic Equivalence and Safety in Treatment of Moderate Facial Rosacea

A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Taro Product to RLD, and Both Active Treatments to a Placebo Control in the Treatment of Moderate Facial Rosacea

Last checked: Nov 19, 2026Latest source record: Mar 19, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 1,116 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,116

Actual

Start

Dec 12, 2017

Primary completion

Aug 9, 2018

Study completion Sep 28, 2018

Sponsor

Sponsor type
Industry
First posted
Sep 28, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To demonstrate the superiority of the efficacy of the test and reference products over that of the placebo control in the treatment of moderate facial rosacea.

Conditions

  • Rosacea

Interventions

  • Azelaic acid foam 15%Drug

    Azelaic acid foam 15%

  • Finacea® (Azelaic acid Foam) 15%Drug

    Azelaic acid foam 15%

  • Vehicle of the test productDrug

    Vehicle of the test product

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. change in the inflammatory lesion countsTime frame: 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Catawba Research, LLC

    Charlotte, North Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.